Jefferson Doyle, MBBCh, MD, PhD, MHS, of the Wilmer Eye Institute at Johns Hopkins University School of Medicine, addresses myopic concerns, such as public health measures including time outdoors, as well as pharmacological approaches including the current atropine data that has been completed and ongoing studies.
Ophthalmology Times®' EyeCon co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and glaucoma specialist Oluwatosin U. Smith MD, from Glaucoma Associates of Texas, discuss some of the highlights of EyeCon 2022.
The test is slated for further clinical development in the first quarter of 2023 and, once FDA approved, will be added to the company's catalog of ophthalmological diagnostic tools available to clinicians throughout North America.
Stephen Pflugfelder, MD, professor and director of the Ocular Surface Center at Baylor College of Medicine in Houston, Texas, presents a challenging diagnostic dilemma.
Rishi Singh, MD, of Cleveland Clinic Florida, touches upon the various advancements that are making a difference for clinicians and patients and reducing their progression in this disease state.
Julius Oatts, MD, covered a range of current considerations for retinopathy of prematurity (ROP), including the updated International Classification for ROP, clinical research, and some of the socioeconomic factors that affect ROP. Oatts is assistant professor and associate residency program director with the Department of Ophthalmology at the University of California, San Francisco.
The company is poised to roll out its eye-tracking amblyopia treatment to the U.S. market.
The American Academy of Ophthalmology has declared December as Safe Toys and Celebrations Month, highlighting how eye-safe toys can help avoid serious eye injuries.
The drug is expected to be available to eye care clinicians in the US during the second half of 2023.
According to the study, attendance improved by 9% and the return on investment totaled $11,387 over a 12-week period.
The IDMC recommended continuation of the study based upon the outcome of the futility analysis.
Harrow Health Inc. announced it has agreed to purchase the exclusive U.S. commercial rights to 5 ophthalmic drugs from Novartis AG for up to $175 million, the company announced today.
The partnership was formalized at the recent International Conference for Initiatives on Organ and Tissue Donation and Transplantation in Abu Dhabi.
The investigators explained that deficient ophthalmologic care is costly to patients, making the identification of groups not receiving adequate care of vital importance
Under the terms of the agreement, Ocular will pay Titan an upfront licensing fee with the potential for additional payments upon reaching certain milestones.
According to researcher, the treatment offers improved retinal sensitivity, visual function, and mobility.
Ophthalmologist discusses the impact of getting older on patients diagnosed with the disease.
AZR-MD-001 is currently being studied to evaluate the safety, efficacy, and tolerability of the study drug in patients with MGD.
The ocular biomarkers studied showed poor to moderate accuracy for detecting the 2 disorders.
CXL has been proven effective to treat patients with corneal ectasias.
The results represent a major step towards first in-human clinical studies for this program - the first potential therapy for patients with geographic atrophy secondary to AMD that addresses the underlying causes of the disease.
Receiving FDA orphan drug designation allows the company to proceed with plans to advance the development of BRM424, a novel, first-in-class, potential treatment for neurotrophic keratitis.
The Ernest E. Tschannen Eye Institute is dedicated to eye care and sight restoration through technology, pioneering research and eye care clinicians.
According to the company, the NDA is supported by positive phase data demonstrating the rapid reversal of dilated eyes and favorable safety profile in pediatric and adult subjects.
Researchers from the Deutsches Zentrum für Neurodegenerative Erkrankungen and the Center for Regenerative Therapies Dresden at TU Dresden have found that visual cells in the human retina may not simply die in some diseases, but are mechanically transported out of the retina beforehand.
According to researchers, cells within retinal blood vessels are endowed with a previously unappreciated ability to acquire resistance against the damaging effects of hyperglycemia in patients with diabetes mellitus.
SPVN06 is a breakthrough gene therapy approach aimed at stopping or slowing disease progression in patients affected by IRDs and dry age-related macular degeneration (AMD), regardless of their genetic background.
Weigh in on this month's survey question. The poll will be open until December 16, 2022.
OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision loss due to mutations in the LCA5 gene, which causes one of the most severe forms of early-onset blinding disease Leber congenital amaurosis.
In an effort to educate the public on GA, Prevent Blindness has created a variety of resources for patients in English and Spanish.
